OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 87.82% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 88.29%, a 12.98% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 78.15%, a 8.45% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 85.36%, a 2.13% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 87.22%, a 10.17% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 78.18%, a 8.02% decline from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 85.00%, a 1.56% decline from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 86.35%, a 8.33% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 79.71%, a 2.79% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 87.82% 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 88.29% 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | 78.18% 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | 78.10% 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 78.08% 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | 78.15% 10-Q · filed 2026-05-12 | ||||
| 2024-12-31 | 85.00% 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | 85.10% 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | 85.24% 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | 85.36% 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | 86.35% 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | 86.71% 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | 87.22% 10-Q · filed 2024-08-06 | 86.88% 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | 87.22% 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | 79.71% 10-K · filed 2024-03-11 | ||||
| 2022-09-30 | 79.55% 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | 79.33% 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | 79.17% 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | 77.55% 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | 77.07% 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | 77.08% 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 77.34% 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | 76.69% 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |